Reuters logo
BRIEF-CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial
2016年11月21日 / 下午1点42分 / 1 年前

BRIEF-CEL-SCI submits response to FDA in connection with partial clinical hold on phase 3 clinical trial

Nov 21 (Reuters) - Cel-sci Corp :

* CEL-SCI Corp - submitted response to FDA regarding partial clinical hold of CEL-SCI’s phase 3 clinical trial of its investigational drug multikine

* CEL-SCI submits response to fda in connection with partial clinical hold on phase 3 clinical trial Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below